2/22/2008

California-based PDL Biopharma completed the $240 million sale of its antibody manufacturing plant in Minnesota to Danish company Genmab A/S in a move to reduce its assets. The deal, which includes access to a leased development lab and other equipment, allows Genmab to supply clinical quantities of antibodies for PDL studies and retain the plant's 170 workers.

Related Summaries